0001209191-20-064857.txt : 20201222 0001209191-20-064857.hdr.sgml : 20201222 20201222165526 ACCESSION NUMBER: 0001209191-20-064857 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201221 FILED AS OF DATE: 20201222 DATE AS OF CHANGE: 20201222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ho Tony W CENTRAL INDEX KEY: 0001713637 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 201408743 MAIL ADDRESS: STREET 1: CRISPR THERAPEUTICS AG STREET 2: 610 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-21 0 0001674416 CRISPR Therapeutics AG CRSP 0001713637 Ho Tony W C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 Executive VP, Head of R&D Common Shares 2020-12-21 4 M 0 23551 16.90 A 57515 D Common Shares 2020-12-21 4 S 0 1700 148.11 D 55815 D Common Shares 2020-12-21 4 S 0 900 149.18 D 54915 D Common Shares 2020-12-21 4 S 0 1600 150.16 D 53315 D Common Shares 2020-12-21 4 S 0 1100 151.58 D 52215 D Common Shares 2020-12-21 4 S 0 500 152.41 D 51715 D Common Shares 2020-12-21 4 S 0 1400 147.05 D 50315 D Common Shares 2020-12-21 4 S 0 8400 148.38 D 41915 D Common Shares 2020-12-21 4 S 0 5000 149.73 D 36915 D Common Shares 2020-12-21 4 S 0 2951 150.61 D 33964 D Stock Option (right to buy) 16.90 2020-12-21 4 M 0 23551 0.00 D 2027-08-01 Common Shares 23551 236449 D Includes 217 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.44 to $148.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.755 to $150.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.04 to $152.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.00 to $147.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.19 to $149.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.20 to $150.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.44 to $151.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% vested on 8/1/2018 and the remaining 75% vest in 36 equal monthly installments on the final day of each succeeding calendar month. /s/ Michael Esposito, attorney-in-fact 2020-12-22